Skip to contentS
Sonoma Pharmaceuticals, Inc.
S
SNOASonoma Pharmaceuticals, Inc. Q1 2027 · 10-Q
Revenue$6.41M$6.41M+59.6% vs Q1 2026 Net Income-$330.00K-$330.00KN/M vs Q1 2026 EPS Diluted-$0.09-$0.09N/M vs Q1 2026 Gross Profit$2,577,000+76.0% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sonoma Pharmaceuticals, Inc. · CIK 1367083 · Engraved from SEC EDGAR
Operating Cash Flow-$649,000N/M Free Cash Flowderived-$651,000N/M Margins · derivedGross margin40.2%+3.8 pt vs Q1 2026
Operating margin-0.6%+26.6 pt vs Q1 2026
Net margin-5.2%+25.8 pt vs Q1 2026
ended Jun 30, 2026 · filed Aug 6, 2026 · 37 d after period end